Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection

Giuseppe M C Rosano; Cristiana Vitale; Antonello Silvestri; Massimo Fini

doi:10.1016/j.maturitas.2003.09.015

Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection

Giuseppe M C Rosano, Cristiana Vitale, Antonello Silvestri, Massimo Fini

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Estrogen therapy causes changes in a variety of cardiovascular risk factors, including insulin resistance, lipoprotein profile, haemostasis, coronary atherosclerosis and vascular reactive, that suggest a potential cardioprotective effect in postmenopausal women. With respect to the role of adjunctive progestins, currently available data suggest that the cardiovascular effects may differ depending on the type, dosage and route of administration of the progestin. Androgenic progestins antagonise the favourable cardiovascular effect of estrogens, whilst non-androgenic progestins do not impair, or may even enhance, the beneficial effect of estrogens. Therefore, less androgenic progestins would appear to be the agent of choice for combined hormone therapy in postmenopausal women with cardiovascular risk factors.

Original language	English
Journal	Maturitas
Volume	46
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/j.maturitas.2003.09.015
Publication status	Published - Dec 10 2003

Keywords

Cardioprotection
Diabetes
Endothelial function
Hormone replacement therapy
Metabolic and vascular effect
Progestins

ASJC Scopus subject areas

Ageing
Obstetrics and Gynaecology

Access to Document

10.1016/j.maturitas.2003.09.015

Cite this

@article{4d9b02c8e2aa4af5bcfa1739d9b0b478,

title = "Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection",

abstract = "Estrogen therapy causes changes in a variety of cardiovascular risk factors, including insulin resistance, lipoprotein profile, haemostasis, coronary atherosclerosis and vascular reactive, that suggest a potential cardioprotective effect in postmenopausal women. With respect to the role of adjunctive progestins, currently available data suggest that the cardiovascular effects may differ depending on the type, dosage and route of administration of the progestin. Androgenic progestins antagonise the favourable cardiovascular effect of estrogens, whilst non-androgenic progestins do not impair, or may even enhance, the beneficial effect of estrogens. Therefore, less androgenic progestins would appear to be the agent of choice for combined hormone therapy in postmenopausal women with cardiovascular risk factors.",

keywords = "Cardioprotection, Diabetes, Endothelial function, Hormone replacement therapy, Metabolic and vascular effect, Progestins",

author = "Rosano, {Giuseppe M C} and Cristiana Vitale and Antonello Silvestri and Massimo Fini",

year = "2003",

month = dec,

day = "10",

doi = "10.1016/j.maturitas.2003.09.015",

language = "English",

volume = "46",

journal = "Maturitas",

issn = "0378-5122",

publisher = "Elsevier Ireland Ltd",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Metabolic and vascular effect of progestins in post-menopausal women

T2 - Implications for cardioprotection

AU - Rosano, Giuseppe M C

AU - Vitale, Cristiana

AU - Silvestri, Antonello

AU - Fini, Massimo

PY - 2003/12/10

Y1 - 2003/12/10

N2 - Estrogen therapy causes changes in a variety of cardiovascular risk factors, including insulin resistance, lipoprotein profile, haemostasis, coronary atherosclerosis and vascular reactive, that suggest a potential cardioprotective effect in postmenopausal women. With respect to the role of adjunctive progestins, currently available data suggest that the cardiovascular effects may differ depending on the type, dosage and route of administration of the progestin. Androgenic progestins antagonise the favourable cardiovascular effect of estrogens, whilst non-androgenic progestins do not impair, or may even enhance, the beneficial effect of estrogens. Therefore, less androgenic progestins would appear to be the agent of choice for combined hormone therapy in postmenopausal women with cardiovascular risk factors.

AB - Estrogen therapy causes changes in a variety of cardiovascular risk factors, including insulin resistance, lipoprotein profile, haemostasis, coronary atherosclerosis and vascular reactive, that suggest a potential cardioprotective effect in postmenopausal women. With respect to the role of adjunctive progestins, currently available data suggest that the cardiovascular effects may differ depending on the type, dosage and route of administration of the progestin. Androgenic progestins antagonise the favourable cardiovascular effect of estrogens, whilst non-androgenic progestins do not impair, or may even enhance, the beneficial effect of estrogens. Therefore, less androgenic progestins would appear to be the agent of choice for combined hormone therapy in postmenopausal women with cardiovascular risk factors.

KW - Cardioprotection

KW - Diabetes

KW - Endothelial function

KW - Hormone replacement therapy

KW - Metabolic and vascular effect

KW - Progestins

UR - http://www.scopus.com/inward/record.url?scp=0345167225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345167225&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2003.09.015

DO - 10.1016/j.maturitas.2003.09.015

M3 - Article

C2 - 14670642

AN - SCOPUS:0345167225

VL - 46

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - SUPPL. 1

ER -

Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this